BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 6, 2026
Home » Authors » Anette Breindl

Articles by Anette Breindl

Human anatomy

Sex disparities of lupus recapitulated in mouse model

April 25, 2022
By Anette Breindl
A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men.
Read More
Stroke illustration: brain, artery, neurons

Astrocyte-produced enzyme affects neuronal activity, stroke outcomes

April 21, 2022
By Anette Breindl
By altering the balance between neuronal excitation and inhibition, researchers have reduced cell death and improved outcomes in animal models of stroke.
Read More
CAR T cell attacking cancer cells

Testing viruses, vaccines, to increase solid tumor CAR T persistence

April 20, 2022
By Anette Breindl
Solid tumors have been a tougher nut to crack for CAR T cells than B-cell cancers, for two main reasons. Solid tumors have an inhibitors microenvironment that has made it difficult to get durable responses. And identifying antigens as specific as the B-cell markers CD19 and CD22 has been challenging, leading to problems with on-target, off-tumor toxicity.
Read More
3D head brain cancer

AACR 2022: Understanding cancer’s brain is new microenvironment frontier

April 14, 2022
By Anette Breindl
The tumor microenvironment is critical for the ability of cancers to survive and grow, and some aspects of the microenvironment are studied, and targeted, accordingly. Tumor immunology is one of the most active areas of cancer research and has become a pillar of treatment. Others, not so much. “The nervous system is the last component of the microenvironment that people have left completely unrecognized,” Humsa Venkatesh told BioWorld. Even in brain tumors and metastases, where the presence of neurons is glaringly obvious, there has been little attention to how the two interact until recently.
Read More
Digital cancer cells illustration

AACR 2022: Viruses, vaccines, ventricular delivery help solid tumor CAR Ts

April 13, 2022
By Anette Breindl
“We’re still a far cry from reproducible, durable benefits” with CAR T cells targeting solid tumors, Crystal Mackall told the audience at the 2022 annual meeting of the American Association for Cancer Research (AACR). But “we’re beginning to see some signals.” Mackall is the founding director of the Stanford Center for Cancer Cell Therapy.
Read More
AACR 2022

With ADCs established, branching out to irregular conjugation

April 11, 2022
By Anette Breindl
With 11 approved therapeutics in a diversity of targets and indications, antibody-drug conjugates (ADCs) have proved their clinical mettle. But they have not yet reached their full clinical potential, which, in the opinion of Astrazeneca plc’s Kenneth Thress, could transform patient care. The strength of ADCs, he told the audience at an educational session at the 2022 annual meeting of the American Association for Cancer Research (AACR 2022), is that it can turn anything into a targeted therapy.
Read More
Cancer cells

Propionate metabolism plays role in metastatic ability

April 11, 2022
By Anette Breindl
Investigators at Weill Cornell Medical College have identified propionate metabolism as a contributor to the ability of cancer cells to establish metastases, establishing new basic insights into cancer metastases as well as potential therapeutic targets.
Read More
Red blood cells and coronavirus

ACE2-independent blood cell infection linked to severe COVID

April 7, 2022
By Anette Breindl
Investigators at Boston Children's Hospital have demonstrated that SARS-CoV-2 infection of blood monocytes and lung macrophages in the lung could kill the cells via pyroptosis, increasing inflammation and leading to severe COVID-19.
Read More
Red blood cells and coronavirus

ACE2-independent blood cell infection linked to severe COVID

April 6, 2022
By Anette Breindl
Investigators at Boston Children's Hospital have demonstrated that SARS-CoV-2 infection of blood monocytes and lung macrophages in the lung could kill the cells via pyroptosis, increasing inflammation and leading to severe COVID-19.
Read More
Illustration of DNA, magnifying glass

Telomere to telomere, the human genome is done

April 5, 2022
By Anette Breindl
There is a project management joke that the first 90% of a project takes 90% of the time, whereas the last 10% of the project takes the other 90% of the time.
Read More
Previous 1 2 … 41 42 43 44 45 46 47 48 49 … 401 402 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing